Document is current

Article History

First Online: 28 January 2025

Disclosures

: James Harding has received research support from NCI P30-CA008748, NCI U01 CA238444 04, the Society of Memorial Sloan Kettering Cancer Center, Experimental Therapeutics Center, and Cycle for Survival. J.J.H. has received additional research support from AbbVie, Bristol Myers Squibb, Boehringer Ingelheim, CytomX, Debiopharm, Eli Lilly, Genoscience, Incyte, Kinnate Biopharma, Loxo @ Lilly, Novartis, Polaris, Pfizer, Tvardi, Zymeworks, and Yiviva and consulting fees from Adaptimmune, Astrazenica, Bristol Myers Squibb, Exelexis, Elevar, Eisai, Genoscience (uncompensated), Hepion, Imvax, Merck (DSMB) Medivir, QED, RayzeBio, Servier, Tempus, Tyra, and Zymeworks (uncompensated). Jeffrey Drebin declares Equity shares of ALNY and IONS purchased via a brokerage account. Andrea Cercek receives advisory fees from Abbvie, Amgen, Agents, Daiichi Snayko, GSK, Merck, Janssen, Pfizer/Seagen, Regeneron, and Roche and research funding from GSK and Pfizer/Seagen. Eileen O'Reilly received research funding to institution from Genentech/Roche, BioNTech, AstraZeneca, Arcus, Elicio, Parker Institute, NIH/NCI, Digestive Care, Break Through Cancer, and Agenus; consulting fees/DSMB from Arcus, AstraZeneca, Ability Pharma, Alligator BioSciences, Agenus, BioNTech, Ipsen, Merck, Moma Therapeutics, Novartis, Syros, Leap Therapeutics, Astellas, BMS, Fibrogen, Revolution Medicines, Regeneron, Merus, and Tango and from Abbvie (spouse); and other support from American Association of Cancer Research, American Society of Clinical Oncology, Imedex, Research To Practice, SU2C. Alice Wei received consulting fees from Histosonics (DSMB member) and clinical trial funding from Ipsen. John Strickler has a consultant or advisory role with Abbvie, Amgen, Astellas, AstraZeneca, Bayer, Beigene, BMS, Daiichi-Sankyo, Eli Lilly, GE Healthcare, GSK, Ipsen, Johnson and Johnson, Jazz Pharmaceuticals, Merck, Natera, Pfizer, Roche/Genentech, Regeneron, Sanofi, Taiho, Takeda, and Xilio Therapeutics; stock options from Triumvira Immunologics; and research funding or contracted research from Abbvie, Amgen, Apollo Therapeutics, AStar D3, Bayer, Beigene, Curegenix, Daiichi-Sankyo, Eli Lilly, Erasca, GSK, Leap Therapeutics, Novartis, Pfizer, Quanta Therapeutics, Revolution Medicines, and Roche/ Genentech.